Business Wire

EverZinc Invests in Zano®

4.12.2018 16:30:00 EET | Business Wire | Press release

Share

EverZinc, the leading global provider of specialty zinc materials, today announced an investment of more than 5 Million Euros in order to increase the production capacity of the Zano® (ultra-fine zinc oxide) product line. Production capacity of EverZinc has been increased by 30% in 2018 and will increase further by another 30% in 2019. EverZinc is also investing in an additional Zano® production line, which is scheduled to be operational from Q1 2020 onwards. This new line will expand EverZinc’s current Zano capacity by another 50%. In total EverZinc is going to triple the production capacity of Zano® in this 48-month period.

The market for UV filters is envisaging major changes, and there is a growing demand for ultra-fine zinc oxide as a mineral UV filter (due to a higher public awareness for UV-A protection, an increasing worldwide interest for natural UV filters, the ban on the chemical filters oxybenzone and octinoxate in several island regions, and the ECHA official opinion about ultra-fine TiO2). “This worldwide trend which is accelerating quickly has resulted in an unforeseen expansion of the zinc oxide suncare market,” said Vincent Dujardin, EverZinc’s Chief Executive Officer. “EverZinc is dedicated to invest in new production capacity of Zano® to support the growth of the zinc-oxide-based sunscreen and skincare market because we believe in the superior characteristics of Zano®, combining broadband UVA/UVB protection and a high level of transparency. Besides, it offers a natural solution to replace chemical filters.”

Following this Capex expenditure, EverZinc is also raising Zano®’s price for material delivered from 1 January 2019 onwards. “Zano®’s price has been stable for many years despite severe cost increases related to energy inflation, zinc’s higher price, carbon emission rights, and staff costs,” concluded Dujardin.

About EverZinc

EverZinc, an OpenGate Capital portfolio company, is committed to creating products that matter. The company is a global provider of specialty zinc materials, including fine zinc powders; zinc oxides; battery zinc powders; and Zano®, an ultra-fine zinc oxide. EverZinc products are used in a wide variety of applications, including corrosion inhibiting paints, performance tires, pharmaceuticals, ceramics, glass, sunscreen, alkaline batteries, and other products. With manufacturing operations located in Belgium, the Netherlands, Norway, China, and Malaysia, EverZinc processes more than 180,000 tons of materials of which 40% are recycled and refined at eight production sites to serve its growing global customer base. Learn more at www.everzinc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact
Grégory Sacré
gregory.sacre@everzinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting Strengthens Digital Transformation Capabilities with Weexa30.4.2026 16:30:00 EEST | Press release

Andersen Consulting enters into a Collaboration Agreement with Weexa, a global provider of digital transformation, B2B integration, and supply chain digitalization solutions. Headquartered in France, Weexa delivers end-to-end services that help organizations streamline, secure, and scale their digital ecosystems. The firm specializes in B2B data-flow management and digitalization, enabling seamless communication between applications both within and across organizations through technologies such as EDI, APIs, and e-invoicing. Weexa also provides SAP integration and supply chain solutions spanning warehouse and transport management, alongside strategic consulting, project delivery, and third-party application maintenance. Serving organizations across the food, retail, wholesale, logistics, transportation, automotive, healthcare, and media sectors, Weexa supports global businesses in optimizing performance while meeting evolving regulatory and digital-compliance requirements. “Collaborati

SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 16:22:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et

Experian Announces Agent Trust to Power Trusted AI Driven Commerce30.4.2026 16:00:00 EEST | Press release

Experian today announced Experian Agent Trust™, a first-of-its-kind framework that establishes a secure, verifiable link between consumers and AI agents, bringing identity, and accountability to AI-driven transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430719198/en/ Experian Announces Agent Trust to Power Trusted AI Driven Commerce. As AI agents begin to search and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer driven by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust addresses this challenge through a new “Know Your Agent” (KYA) framework, extending identity verification into the age of AI. The framework ensures that agent-initiated transactions are grounded in verified consumer identity. “Agen

Meet the AI-powered fan companion: TGR Haas F1 Team RaceMate powered by Infobip30.4.2026 16:00:00 EEST | Press release

Global AI-first cloud communications platform Infobip and TGR Haas F1 team are launching ‘TGR Haas F1 Team RaceMate powered by Infobip’, an AI-powered conversational fan companion on Apple Messages for Business and WhatsApp Business Platform. Always-on and always available, it delivers race intelligence for TGR Haas F1 Team: team race intelligence, grid positions, qualifying outcomes, sprint results, and full session schedules. The AI agent tracks drivers Ollie Bearman and Esteban Ocon with their individual championship standings and performance data in conversational format. The agent draws from a knowledge base covering driver biographies, team history, and circuit data, adapting to each user's knowledge level. Every interaction begins with a schedule check, ensuring fans always know what's happening right now. It proactively surfaces relevant information, suggests next actions, and maintains conversational flow to keep every interaction effortless and engaging. Delivered in short, s

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release

Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye